(Q48031013)

7 February 2018

title

A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. (English)

1 reference

7 February 2018

main subject

phase II clinical trial

0 references

0 references

1 reference

1 reference

M N Levine

1

1 reference

7 February 2018

C Gu

2

1 reference

7 February 2018

H A Liebman

3

1 reference

7 February 2018

C P Escalante

4

1 reference

7 February 2018

S Solymoss

5

1 reference

7 February 2018

D Deitchman

6

1 reference

7 February 2018

L Ramirez

7

1 reference

7 February 2018

J Julian

8

1 reference

7 February 2018

publication date

1 May 2012

1 reference

7 February 2018

Journal of Thrombosis and Haemostasis

published in

1 reference

7 February 2018

volume

10

1 reference

7 February 2018

issue

5

1 reference

7 February 2018

page(s)

807-814

1 reference

7 February 2018

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

10.1111/J.1538-7836.2012.04693.X

21 January 2018

Identifiers

DOI

1 reference

7 February 2018

PubMed ID

22409262

1 reference

7 February 2018